Founder and CEO of a VC-backed bioproduction company. Brings rare dual fluency in biology and business — capable of leading both the lab floor and the boardroom.
Exosome Market Focus
Last 3 years deeply focused on the exosome sector, with extensive due diligence on cross-border operations, manufacturing partnerships, regulatory landscape, clinic/doctor relationships globally, and deep competitive knoweldge.
Technical / Core Expertise
Bioreactor Systems
10+ years designing scalable bioreactor systems up to 200L for therapeutic-grade biologics manufacturing.
Hollow Fiber Perfusion
Hands-on operator across multiple hollow fiber perfusion platforms - the gold standard for high yield exosome production at clinical scale.
GMP Bioprocess Engineering
End-to-end GMP process design across multiple product lines, from IND-enabling studies through commercial-scale manufacturing readiness.
The rare operator who understands both the biology and the business.
Market Analysis
A Market at an Inflection Point
$1.6B+
Market by 2034
Exosome based regenerative aesthetics projected market size, representing a high growth segment with accelerating clinical adoption.
2025–26
Regulatory Window
Florida SB1768 are opening commercial avenues for US produced therapeutic exosomes — right now.
Competitive Differentiation
Exo-Top's GMP certified, US produced, MSC derived exosomes offer a decisive quality and compliance advantage over key competitors:
Revenue Opportunity
Potential Clients: Scale & Buying Power
The addressable buyer universe is substantial, spanning four high-value clinical segments with meaningful per-account revenue potential.
Total Addressable Buyer Universe
11,000–19,500 qualified accounts globally across all four segments, with strong concentration in the US, Mexico, and Asia-Pacific.
Year 1 Revenue Target
Conservative ramp of 40–80 activated accounts translates to $2.5M–$5.0M in first-year revenue — achievable with existing network and no cold outreach required.
Geographic Strategy
Countries With Active Contacts
USA / Florida — Anchor Market
$500M+ domestic market. 1,500–3,000 national buyers, with Florida as the highest-density state for aesthetic and longevity medicine. Favorable state-level legislation (SB1768) creates immediate commercial entry. CEO is Florida-based.
Latin America / Mexico — Medical Tourism Hub
$200M regional market. Mexico is the anchor — a globally recognized medical tourism destination with 400–800 qualified buyers in-country alone. Existing relationships accelerate market entry and support cross-border patient referral flows.
Asia / Taiwan — APAC Growth Channel
$900M Far East market. Existing manufacturing partner relationships and an established APAC clinical network provide a significant structural advantage. Taiwan serves as the regional gateway for broader Asia-Pacific commercial expansion.
Compensation Structure
Expected Compensation & Structure
Total Package Overview
$150,000–$180,000
Base Salary
Commensurate with CEO/founder-operator responsibility.
US-based with regular travel to Mexico and Asia-Pacific for clinical partner engagement.
Full Compensation Components
Base Salary
$150,000–$180,000 USD/year, reflecting the operational and executive scope of the role.
Equity Participation
Commensurate with a CEO/founder-operator contribution — structured to align long term incentives with Exo-Top's growth trajectory and NurExone's shareholder value creation.
Performance Bonus
Milestone tied bonus structure linked directly to revenue targets, account acquisition, and key commercial deliverables — ensuring accountability and upside alignment.
Investment Thesis
Why This Works
Three forces are converging simultaneously — and Exo-Top sits at the exact intersection of all three.
The Right Product
GMP-certified, US produced, MSC derived exosomes. Regulatory ready, clinically credible, and meaningfully differentiated from every competitor in the current market.
The Right Moment
2025–2026 US state legislation is creating a legal commercial runway that did not exist 18 months ago. First mover advantage is available — but only briefly.
The Right Operator
A CEO with bioproduction depth, prior VC-backed company leadership, and an established exosome clinical network. Day one execution capacity — no ramp up period required.
Exo-Top is a near term revenue opportunity, not a speculative bet. The product is real, the market is open, and the operator is ready.
Financial Planning
Year 1 Budget — Distribution Model
Exo-Top purchases finished GMP-grade product from NurExone at cost and resells to clinics and physicians at margin. No production infrastructure required.
Headcount (3 FTE)
TOTAL fully loaded (incl. 20% benefits): ~$348,000
Operating Expenses
P&L Summary
Asset-light model. Under $1M to launch. Profitable in Year 1 at both scenarios.